Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
Completed · Phase 1
Conditions studied: Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma, Pheochromocytoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
In brief
RATIONALE: Radiolabeled octreotide can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. PURPOSE: This phase I trial is to study the safety and effectiveness of radiolabeled octreotide in treating children who have advanced or refractory solid tumors.
Key facts
- Study ID
- NCT00049023
- Run by
- O'Dorisio, M S
- People needed
- 27
- Starts
- 2002-01-01
- Expected to finish
- 2011-08-01
- Last updated by the study team
- 2016-06-21
Who can join
Age: 2 and older, up to 25. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Holden Comprehensive Cancer Center at University of Iowa — Iowa City, Iowa, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.